- Home
- CSBR vs ATOS Comparison
CSBR vs ATOS Comparison
Compare CSBR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- ATOS
- Stock Information
- Founded
- CSBR 1985
- ATOS 2009
- Country
- CSBR United States
- ATOS United States
- Employees
- CSBR N/A
- ATOS N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- CSBR Health Care
- ATOS Health Care
- Exchange
- CSBR Nasdaq
- ATOS Nasdaq
- Market Cap
- CSBR 111.4M
- ATOS 107.2M
- IPO Year
- CSBR 1986
- ATOS 2012
- Fundamental
- Price
- CSBR $8.33
- ATOS $0.94
- Analyst Decision
- CSBR Strong Buy
- ATOS Strong Buy
- Analyst Count
- CSBR 1
- ATOS 3
- Target Price
- CSBR $12.00
- ATOS $6.17
- AVG Volume (30 Days)
- CSBR 39.6K
- ATOS 1.5M
- Earning Date
- CSBR 09-10-2025
- ATOS 08-11-2025
- Dividend Yield
- CSBR N/A
- ATOS N/A
- EPS Growth
- CSBR N/A
- ATOS N/A
- EPS
- CSBR 0.46
- ATOS N/A
- Revenue
- CSBR $58,591,000.00
- ATOS N/A
- Revenue This Year
- CSBR $15.11
- ATOS N/A
- Revenue Next Year
- CSBR $7.80
- ATOS N/A
- P/E Ratio
- CSBR $17.71
- ATOS N/A
- Revenue Growth
- CSBR 19.03
- ATOS N/A
- 52 Week Low
- CSBR $3.60
- ATOS $0.55
- 52 Week High
- CSBR $11.99
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- CSBR 64.00
- ATOS 58.44
- Support Level
- CSBR $7.16
- ATOS $0.81
- Resistance Level
- CSBR $9.63
- ATOS $0.88
- Average True Range (ATR)
- CSBR 0.64
- ATOS 0.05
- MACD
- CSBR 0.11
- ATOS 0.01
- Stochastic Oscillator
- CSBR 69.06
- ATOS 84.07
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.